Drug intelligence / Profile preview

TKP-AL-01

Development stage: Preclinical
Lead developer: TheraCea Pharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

TKP-AL-01 is a preclinical-stage 18F-labeled peptide radiotracer developed by TheraCea Pharma for the imaging of neurological disorders. The agent is designed for use in Positron Emission Tomography (PET) to visualize specific biological targets associated with neurological pathology. It leverages TheraCea's specialized radiolabeling technology, which allows for the efficient incorporation of the Fluorine-18 isotope into peptide sequences. This platform aims to provide high-affinity, specific imaging agents that can improve the diagnostic capabilities and monitoring of various brain-related conditions.

Beyond the preview

Go deeper on TKP-AL-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKP-AL-01.

Explore the full profile